Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer

NCT02996214 is registered in ClinicalTrials.gov with Nanjing Luye Sike Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02996214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02996214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer
Lead sponsor
Nanjing Luye Sike Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Unknown status
Start date
November 30, 2016
Completion date
June 30, 2020
Enrollment
536 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous non-small-cell lung cancer